Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

Share this video  

SMR 2024 | Evaluating the role of gut and tumor microbiome in melanoma immunotherapy

Saman Maleki • 22 Oct 2024
SMR 2024
Melanoma Skin Cancer

Saman Maleki, PhD, Lawson Health Research Institute, London, Canada, comments on emerging research on modulating the gut and skin microbiomes to enhance immunotherapy in melanoma. While most efforts focus on adjusting the gut microbiome to influence systemic immune response, new studies are examining the tumor’s local microbiome, especially for skin melanomas that can be biopsied. Insights into the tumor microbiome’s unique role in immune modulation could also open novel avenues for personalized immunotherapy. This interview took place at the 21st International Congress of the Society for Melanoma Research (SMR) in New Orleans, LA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.

More from Saman Maleki

Microbiome modulation strategies in melanoma therapy
1:28
Microbiome modulation strategies in melanoma therapy
Saman Maleki • 22 Oct 2024
Fecal microbial transplantation combined with anti-PD-1 therapy in melanoma
0:40
Fecal microbial transplantation combined with anti-PD-1 therapy in melanoma
Saman Maleki • 22 Oct 2024
IL-12 + IL-27 upregulate CD39 expression on CD8+ T-cells + affect CD39+CD8+ T-cell effector function
3:28
IL-12 + IL-27 upregulate CD39 expression on CD8+ T-cells + affect CD39+CD8+ T-cell effector function
Saman Maleki • 2 Nov 2022
Microbiome modification with fecal transplant before IO to reduce primary resistance in melanoma
4:17
Microbiome modification with fecal transplant before IO to reduce primary resistance in melanoma
Saman Maleki • 2 Nov 2022

Related Videos

Predictors of toxicity and tolerability with lifileucel in advanced melanoma
1:18
Predictors of toxicity and tolerability with lifileucel in advanced melanoma
Alexandra Haugh • 30 May 2026
The Phase I/II trial of dendritic cell vaccine DOC1021 for refractory melanoma
1:00
The Phase I/II trial of dendritic cell vaccine DOC1021 for refractory melanoma
Alexandra Haugh • 30 May 2026
Real-world safety of adoptive cellular therapy with lifileucel in patients with advanced melanoma
2:41
Real-world safety of adoptive cellular therapy with lifileucel in patients with advanced melanoma
Alexandra Haugh • 30 May 2026
A Phase II trial of IO102-IO103 and nivolumab-relatimab in melanoma
1:05
A Phase II trial of IO102-IO103 and nivolumab-relatimab in melanoma
James Smithy • 31 May 2026
The content of VJOncology is intended for healthcare professionals